GRCE
Income statement / Annual
Last year (2026), Grace Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2026, Grace Therapeutics Inc.'s net income was -$7.79 M.
See Grace Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
03/31/2026 |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$309.32 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$119.94 K
|
$0.00
|
$3.12 M
|
$2.68 M
|
$1.93 M
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$189.38 K
|
$0.00
|
-$3.12 M
|
-$2.68 M
|
-$1.93 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0.61
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.41 M
|
$13.54 M
|
$6.35 M
|
$13.49 M
|
$6.95 M
|
$6.59 M
|
$31.92 M
|
$29.37 M
|
$12.13 M
|
$5.38 M
|
| General & Administrative Expenses |
$8.67 M
|
$10.20 M
|
$9.02 M
|
$10.92 M
|
$12.08 M
|
$8.70 M
|
$11.59 M
|
$3.80 M
|
$3.12 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$183.94 K
|
$144.94 K
|
$1.80 M
|
$5.33 M
|
$494.00 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.67 M
|
$10.20 M
|
$9.02 M
|
$11.11 M
|
$12.22 M
|
$10.50 M
|
$16.91 M
|
$4.29 M
|
$3.12 M
|
$575.95 K
|
| Other Expenses |
$7.00 K
|
$9.97 K
|
$2.07 M
|
$45.95 M
|
$311.12 K
|
$9.01 M
|
$0.00
|
$741.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.08 M
|
$23.75 M
|
$17.44 M
|
$70.54 M
|
$19.48 M
|
$26.10 M
|
$48.83 M
|
$34.41 M
|
$15.25 M
|
$5.96 M
|
| Cost And Expenses |
$11.08 M
|
$23.75 M
|
$17.44 M
|
$70.54 M
|
$19.48 M
|
$26.22 M
|
$48.83 M
|
$34.41 M
|
$15.25 M
|
$7.88 M
|
| Interest Income |
$685.00 K
|
$711.00 K
|
$911.00 K
|
$246.00 K
|
$77.00 K
|
$134.42 K
|
$474.96 K
|
$479.17 K
|
$72.32 K
|
$87.90 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$331.65 K
|
$414.18 K
|
$1.05 M
|
$371.62 K
|
$40.79 K
|
| Depreciation & Amortization |
$7.00 K
|
$9.97 K
|
$54.28 K
|
$167.71 K
|
$0.00
|
$1.46 M
|
$4.64 M
|
$2.33 M
|
$2.07 M
|
$1.93 M
|
| EBITDA |
-$11.07 M |
-$23.74 M |
-$15.37 M |
-$24.51 M |
-$19.17 M |
-$15.45 M |
-$45.85 M |
-$36.76 M |
-$14.30 M |
-$5.96 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-49.96
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-83.77
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.58 M
|
$5.57 M
|
-$2.49 M
|
$248.87 K
|
$6.40 M
|
-$5.14 M
|
-$2.15 M
|
-$4.96 M
|
-$1.40 M
|
-$116.74 K
|
| Income Before Tax |
-$9.49 M
|
-$18.18 M
|
-$19.93 M
|
-$70.29 M
|
-$13.08 M
|
-$31.05 M
|
-$50.98 M
|
-$39.37 M
|
-$16.65 M
|
-$8.00 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.70 M
|
-$4.56 M
|
-$2.49 M
|
-$12.91 M
|
-$809.66 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$90.72 K
|
| Net Income |
-$7.79 M
|
-$13.63 M
|
-$17.44 M
|
-$57.39 M
|
-$12.27 M
|
-$31.05 M
|
-$50.98 M
|
-$39.37 M
|
-$16.65 M
|
-$7.91 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
0
|
| EPS |
-0.47 |
-1.13 |
-1.83 |
-7.72 |
-2.02 |
-12.59 |
-28.78 |
-46.58 |
-59.3 |
-34.22 |
| EPS Diluted |
-0.47 |
-1.13 |
-1.83 |
-7.72 |
-2.02 |
-12.59 |
-28.78 |
-46.58 |
-59.3 |
-34.22 |
| Weighted Average Shares Out |
$16.51 M
|
$12.09 M
|
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364.30 K
|
$231.14 K
|
| Weighted Average Shares Out Diluted |
$16.51 M
|
$12.09 M
|
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364.30 K
|
$231.14 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
